The Venture Codex

Participated · Series A · Jun 2026

Vixtra offers financial services for importers, focusing on modernizing an analog foreign-trade ecosystem by providing credit, FX and related products. The company uses stablecoins in its FX transactions and lending processes, which it says enables greater speed and competitive pricing. Vixtra already manages a credit portfolio of R$250 million and reports an ARR of US$12 million. Leadership, led by CEO Leonardo Baltieri, positions the business as a complementary alternative to traditional banks rather than a replacement. The firm intends to accelerate customer acquisition—seeking to increase monthly new clients from about 10 to 20–30—and to introduce new offerings including loans and currency insurance. These plans are cited as core uses for the fresh capital from the Series A round.

Led · Equity · Feb 2026

Founded in 2024 by Nitesh Jain and Sharad Arora, Ethera designs and sells earrings, bracelets, solitaires, pendants and necklaces crafted with IGI-certified lab-grown diamonds and BIS-hallmarked gold. The company currently operates five stores across Bengaluru and Delhi and introduces more than 200 new designs each month. Management plans to open additional locations in the coming weeks while investing in supply-chain systems, technology infrastructure and brand marketing to support scale. Ethera sees India’s lab-grown diamond jewellery segment as a USD 500 million opportunity growing 35–40 percent annually and believes ethical, transparent luxury will drive greater category share by 2030. The recent capital infusion strengthens its ability to expand physical retail reach, deepen supply-chain capabilities and build operational backbone for rapid growth.

Participated · Series C · Mar 2023

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Series B · Jun 2022

Elucid's core product, PlaqueIQ, is an AI-powered computed tomography angiography (CTA) analysis software that objectively quantifies and characterizes arterial plaque and is FDA-cleared. The software simulates histology and is validated against tens of thousands of tissue annotations by pathologists. Elucid is pursuing an additional indication for non-invasive fractional flow reserve measurement (FFRCT) uniquely derived from its PlaqueIQ technology. The plaque analysis software is commercially available in the U.S., UK, EU, and South Korea. The company has been ramping commercial efforts, expanding clinical research and development, and has significantly bolstered its leadership team. Financially, Elucid announced an $80 million Series C and has raised $121 million in total funding since inception. Elucid builds interpretable, validated AI software that non-invasively quantifies atherosclerotic plaque characteristics compared to histopathology, including lipid rich necrotic core. Its machine-learning algorithms characterize tissue types in the artery wall and power applications that derive FFRct, estimate risk of heart attack/stroke, and produce expression-prediction outputs to inform therapeutic selection. The platform enables physicians to diagnose causes of chest pain and detect early-stage heart disease not visible with alternative methods. The software is FDA-cleared and CE-marked and is commercially available in the U.S., Europe, and South Korea. Led by CEO Blake Richards, the company intends to use new funding to accelerate growth and further development efforts. No revenue or user metrics were reported in the article. Elucid develops interpretable, validated AI software (ElucidVivo) to help physicians detect cardiovascular disease and optimize treatment decisions. ElucidVivo is the first FDA-cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics versus histopathology, including lipid-rich necrotic core, and is commercially available in the U.S. and Europe. The company has published studies on deriving fractional flow reserve (FFRct) from vasodilative vessel-wall capacity and on estimating coding and non-coding RNA transcripts (“Virtual Transcriptomics”). Management says the technology aims to reduce invasive procedures, improve diagnostic power, and enable precision medicine for cardiac and neurovascular patients. Recent hires include Jason Bottiglieri as Chief Commercial Officer and Murali Ayyapillai as Vice President of Engineering to support commercialization and product development. The company plans to continue advancing and commercializing its platform to improve outcomes and reduce healthcare costs.

Participated · Series B · Oct 2021

Akadeum Life Sciences pioneers flotation-based cell separation technologies that enable more effective, scalable, and gentle cell isolation. The company commercialized industry-first innovations including scalable negative selection, multiplex separation, microbubble-based nucleic acid extraction, and a high-capacity T cell separation chamber. It recently launched a GMP-compliant product suite designed for use in clinical trials and demonstrated the ability to integrate microbubbles into many existing cell therapy manufacturing tools. Akadeum says its platform has shown therapeutic relevance in preclinical animal models for cancer treatment and is driving adoption through data showing more viable cells, higher yields, and easier workflows versus conventional methods. The company announced a $20M+ financing to scale commercial operations and especially to support customers entering clinical trials. Akadeum has gained industry momentum and engagement from partners and customers including Catalent, Charles River Laboratories, ElevateBio, and Lonza. Akadeum Life Sciences develops a floatation-based, microbubble separation platform (Buoyancy Activated Cell Sorting, BACS™) for sample preparation in research, diagnostics, and cell therapy. Its technology floats target cells, nucleic acids and other biological targets to the top of a sample to enable capture, addressing volume and throughput restrictions of existing methods. The company was the first to commercialize BACS microbubble kits for cell isolation applications. Akadeum positions its solutions as exceeding the performance, system cost, and scalability of current technologies. Future plans stated in the article include advancing global commercialization, developing new business-to-business partnerships, and expanding R&D and new product development. The company is located in Ann Arbor, Michigan. Akadeum Life Sciences develops technology that enables fast, easy removal of target cells from biological samples. Its product uses BACS™ (buoyancy-activated cell sorting) with tiny floating "microbubbles" and disposable microbubble collectors to acquire target cells. The microbubbles are introduced into samples, attach to target cells such as T cells, B cells, or cancer cells, and gently float them to the top for easy capture and removal. The company was founded in 2014 and is led by CEO Brandon McNaughton and CTO John Younger; it is based in Ann Arbor, Michigan. Akadeum raised $1M in seed funding and will use the funds to continue product development and increase sales and marketing. The company plans a Series A financing round in 2016.